AssetMark Inc
RPRX icon

AssetMark Inc’s Royalty Pharma RPRX Stock Holding History

AssetMark Inc’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$610K Buy
10,870
+5,012
+86% +$261K ﹤0.01% 1189
2026
Q1 		$281K Buy
5,858
+2,170
+59% +$95K ﹤0.01% 1270
2025
Q4 		$143K Buy
3,688
+168
+5% +$6.41K ﹤0.01% 1387
2025
Q3 		$124K Buy
3,520
+216
+7% +$7.82K ﹤0.01% 1374
2025
Q2 		$119K Buy
3,304
+2,696
+443% +$89.3K ﹤0.01% 1333
2025
Q1 		$18.9K Buy
608
+270
+80% +$8.56K ﹤0.01% 1718
2024
Q4 		$8.62K Buy
338
+319
+1,679% +$8.46K ﹤0.01% 1820
2024
Q3 		$538 Buy
+19
New +$526 ﹤0.01% 2076
2024
Q1 		– Sell
-9
Closed -$253 – 2088
2023
Q4 		$253 Buy
+9
New +$247 ﹤0.01% 1739
2022
Q4 		– Sell
-83
Closed -$3K – 1651
2022
Q3 		$3K Buy
+83
New +$3.54K ﹤0.01% 1364

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AssetMark Inc's RPRX Position: Q2 2026 in Review

AssetMark Inc increased its Royalty Pharma (RPRX) stake by 86% in Q2 2026, buying an estimated $261K and bringing the position to 10,870 shares worth $610K. The position accounts for ﹤0.01% of the portfolio, ranked #1189.

AssetMark Inc first reported a position in RPRX in Q3 2022 and has held it in 10 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • AssetMark Inc held 10,870 shares of Royalty Pharma worth $610K as of Q2 2026.
  • AssetMark Inc bought 5,012 Royalty Pharma shares in Q2 2026, an estimated $261K.
  • Royalty Pharma made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1189 holding.
  • AssetMark Inc first reported a position in Royalty Pharma in Q3 2022 and has held it in 10 quarters since.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.